SI3416631T1 - Terapevtska sredstva za nevrodegenerativne bolezni - Google Patents

Terapevtska sredstva za nevrodegenerativne bolezni

Info

Publication number
SI3416631T1
SI3416631T1 SI201730071T SI201730071T SI3416631T1 SI 3416631 T1 SI3416631 T1 SI 3416631T1 SI 201730071 T SI201730071 T SI 201730071T SI 201730071 T SI201730071 T SI 201730071T SI 3416631 T1 SI3416631 T1 SI 3416631T1
Authority
SI
Slovenia
Prior art keywords
therapeutic agents
neurodegenerative diseases
neurodegenerative
diseases
therapeutic
Prior art date
Application number
SI201730071T
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SI3416631T1 publication Critical patent/SI3416631T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201730071T 2016-08-11 2017-08-11 Terapevtska sredstva za nevrodegenerativne bolezni SI3416631T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases
EP17767934.7A EP3416631B1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
SI3416631T1 true SI3416631T1 (sl) 2019-09-30

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730071T SI3416631T1 (sl) 2016-08-11 2017-08-11 Terapevtska sredstva za nevrodegenerativne bolezni

Country Status (27)

Country Link
US (3) US20200179320A1 (sl)
EP (2) EP3583940A1 (sl)
JP (3) JP6957602B2 (sl)
KR (3) KR20240068761A (sl)
CN (3) CN116459244A (sl)
AU (2) AU2017308865B2 (sl)
BR (1) BR112019002730A2 (sl)
CA (1) CA3033564A1 (sl)
CY (1) CY1121930T1 (sl)
DK (1) DK3416631T3 (sl)
ES (1) ES2733677T3 (sl)
HR (1) HRP20191055T1 (sl)
HU (1) HUE045043T2 (sl)
IL (3) IL264641B1 (sl)
LT (1) LT3416631T (sl)
MA (2) MA47521A (sl)
MD (1) MD3416631T2 (sl)
ME (1) ME03454B (sl)
MX (2) MX2019001575A (sl)
PL (1) PL3416631T3 (sl)
PT (1) PT3416631T (sl)
RS (1) RS59048B1 (sl)
RU (2) RU2021128045A (sl)
SG (1) SG11201901063SA (sl)
SI (1) SI3416631T1 (sl)
TN (1) TN2019000033A1 (sl)
WO (1) WO2018029658A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7393943B2 (ja) * 2016-08-11 2023-12-07 イントラバイオ リミティド リソソーム蓄積障害に関する医薬組成物及び使用
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
KR102549684B1 (ko) * 2017-10-18 2023-06-29 인트라바이오 리미티드 신경퇴행성 질병에 대한 치료제
US11660279B2 (en) 2018-02-15 2023-05-30 Intrabio Limited Therapeutic agents for treating restless leg syndrome
MX2021006559A (es) * 2018-12-06 2021-08-16 Intrabio Ltd Analogos deuterados de acetil-leucina.
AU2020231189A1 (en) * 2019-03-02 2021-09-30 Intrabio Ltd. Leucine, acetyl leucine, and related analogs for treating disease
JP7432711B2 (ja) * 2019-09-17 2024-02-16 エフ． ホフマン－ラ ロシュ アーゲー 動作障害患者に対する個別化医療の改善
WO2021144720A1 (en) * 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs

Also Published As

Publication number Publication date
CN116492328A (zh) 2023-07-28
BR112019002730A2 (pt) 2019-05-14
CY1121930T1 (el) 2020-10-14
MA43828B1 (fr) 2019-09-30
CA3033564A1 (en) 2018-02-15
KR20220093385A (ko) 2022-07-05
KR20190039227A (ko) 2019-04-10
AU2023202121A1 (en) 2023-05-04
RU2019106506A3 (sl) 2020-10-29
JP2019524822A (ja) 2019-09-05
HUE045043T2 (hu) 2019-12-30
MA47521A (fr) 2021-04-21
HRP20191055T1 (hr) 2019-09-06
ME03454B (me) 2020-01-20
US20200179320A1 (en) 2020-06-11
AU2017308865B2 (en) 2023-04-13
RU2019106506A (ru) 2020-09-17
CN116459244A (zh) 2023-07-21
WO2018029658A1 (en) 2018-02-15
MX2019001575A (es) 2019-08-01
RU2021128045A (ru) 2021-11-16
AU2017308865A1 (en) 2019-02-21
RS59048B1 (sr) 2019-08-30
MD3416631T2 (ro) 2019-09-30
EP3583940A1 (en) 2019-12-25
PL3416631T3 (pl) 2019-11-29
TN2019000033A1 (fr) 2020-07-15
KR20240068761A (ko) 2024-05-17
CN109789114A (zh) 2019-05-21
US20240189267A1 (en) 2024-06-13
JP6957602B2 (ja) 2021-11-02
PT3416631T (pt) 2019-07-11
MX2021006901A (es) 2021-07-07
LT3416631T (lt) 2019-08-26
JP2022003085A (ja) 2022-01-11
DK3416631T3 (da) 2019-07-15
MA43828A (fr) 2018-12-26
SG11201901063SA (en) 2019-03-28
KR102413756B1 (ko) 2022-06-27
ES2733677T3 (es) 2019-12-02
US20230210799A1 (en) 2023-07-06
IL264641B1 (en) 2024-03-01
JP2023175762A (ja) 2023-12-12
IL310801A (en) 2024-04-01
IL264641A (en) 2019-04-30
EP3416631A1 (en) 2018-12-26
EP3416631B1 (en) 2019-05-15
RU2756519C2 (ru) 2021-10-01
IL310799A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
HK1256383A1 (zh) 治療劑
PT3600309T (pt) Combinações terapêuticas para o tratamento de doenças hepáticas
EP3227330C0 (en) TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
IL265902A (en) Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
GB201603104D0 (en) Therapeutic agents
HK1258727A1 (zh) 治療性化合物
GB201516905D0 (en) Treatment of Neurodegenerative diseases
GB201509885D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
IL281869A (en) Medical factor for neurodegenerative disease
IL273929A (en) Therapeutic agents for neurodegenerative diseases
GB201700553D0 (en) Therapeutic agents
GB201617339D0 (en) Therapeutic compounds
GB201616839D0 (en) Therapeutic compounds
GB201513299D0 (en) Therapeutic agents
GB201600376D0 (en) Novel therapeutic agents
SG11201705915VA (en) Therapeutic agent for ischemic diseases
GB201521767D0 (en) Therapeutic agents
IL263821A (en) Medicinal compounds
EP3560505A4 (en) INNOVATIVE THERAPEUTICS FOR PRIONOID DISEASES
GB201517264D0 (en) Therapeutic agents
GB201420348D0 (en) Compounds for treating neurodegenerative diseases